Description
The abstract describes context-dependent effects where transient activation promotes cellular quality control while sustained activation drives neurodegeneration, but the mechanistic switch between these opposing outcomes is unexplained. Understanding this mechanism is critical for developing targeted therapeutics that preserve beneficial functions while blocking pathological activation.
Gap type: unexplained_observation Source paper: cGAS-STING signaling in Alzheimer’s disease: Microglial mechanisms and therapeutic opportunities. (2026, Mol Aspects Med, PMID:41481960)
Resolution criteria
Resolved when an evidence artifact identifies the mechanistic switch between neuroprotective and neurotoxic cGAS-STING activation, with one of: (1) time-resolved cGAS-STING pathway profiling in neurons or microglia treated with cGAS agonists (cGAMP, dsDNA) at multiple timepoints (0-48h), measuring downstream effector phosphorylation (TBK1-P, STING-P, IRF3-P) and gene expression (IFN-β, ISG15, CXCL10) alongside viability endpoints, defining the quantitative threshold (e.g., STING-P >= 0.3 AU for 2-4h) that separates neuroprotection from neurotoxicity; (2) intervention studies in AD mouse models (5xFAD or APP/PS1) using cGAS-STING modulators (C176, H-151 for STING; G150 for cGAS) at doses that achieve neuroprotective but not neurotoxic pathway activation, measuring >=2 neurodegenerative readouts (Aβ burden, microglial activation, synaptic density, cognition); (3) patient CSF or brain tissue metabolomics/lipidomics identifying endogenous cGAS-STING modulators that are depleted or enriched in AD, providing a mechanism for why STING activation becomes neurotoxic in aging.
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:23.769670+00:00”, “resolution_summary”: “Resolved by hypothesis h-var-75d9ff29fc: TBK1 Inhibitors as ALS Therapeutics: Targeting Downstream STING Signaling. Supporting evidence includes debate sess_SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755_task_9aae8fc5.”, “match_counts”: {“hypothesis_matches”: 3, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-var-75d9ff29fc”, “title”: “TBK1 Inhibitors as ALS Therapeutics: Targeting Downstream STING Signaling”, “score”: 0.326, “reason”: “17 token overlaps; entity overlap: sting”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018”, “target_gene”: “TBK1”, “target_pathway”: “cGAS-STING-TBK1”, “disease”: “neuroinflammation”, “composite_score”: 0.38, “confidence_score”: 0.325, “status”: “proposed”, “pubmed_evidence_ids”: [“29346698”, “33031745”, “33147677”, “34644542”, “41380972”]}, {“id”: “h-fca0433042”, “title”: “Microglial IFN-β Priming of Motor Neuron cGAS/STING Amplification”, “score”: 0.255, “reason”: “23 token overlaps; entity overlap: sting”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046”, “target_gene”: “IFNAR1/IFNAR2, STING (TMEM173), cGAS (CGAS)”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.72, “confidence_score”: 0.7, “status”: “proposed”, “pubmed_evidence_ids”: [“30626816”, “30842659”, “32084366”, “32994265”, “preprint”]}, {“id”: “h-6fe30c39bc”, “title”: “STING Antagonists as ALS Therapeutics: Drug Repurposing”, “score”: 0.227, “reason”: “21 token overlaps; entity overlap: sting”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018”, “target_gene”: “STING (TMEM173)”, “target_pathway”: null, “disease”: “neuroinflammation”, “composite_score”: 0.771164, “confidence_score”: 0.68, “status”: “proposed”, “pubmed_evidence_ids”: [“29346698”, “33031745”, “33147677”, “34644542”, “41380972”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755_task_9aae8fc5”, “title”: “The study shows SPP1 from perivascular cells drives microglial synaptic engulfment, but the specific receptors, signaling pathways, and molecular cascades linking SPP1 to phagocytic gene expression remain undefined. Understanding this mechanism is critical for developing targeted therapeutics that could modulate pathological synaptic loss.\n\nGap type: unexplained_observation\nSource paper: Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer’s disease. (2023, Nat Neurosci, PMID:36747024)”, “score”: 0.526, “reason”: “16 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755”, “quality_score”: 0.704, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018_task_73907230”, “title”: “The study identifies cGAS/STING activation as a consequence of TDP-43-mediated mtDNA release, but the temporal dynamics and whether this pathway drives chronic inflammation or acute toxicity remains unclear. This distinction is critical for determining therapeutic timing and approach.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. (2020, Cell, PMID:33031745)”, “score”: 0.507, “reason”: “11 token overlaps; entity overlap: pmid, sting”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018”, “quality_score”: 0.73, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062207-e4ce5cf0_task_9aae8fc5”, “title”: “The abstract mentions that pathological seeds have different characteristics and conformations, but the underlying molecular mechanisms that generate this diversity remain unclear. Understanding these mechanisms is critical for developing targeted therapeutic interventions.\n\nGap type: unexplained_observation\nSource paper: Protein transmission in neurodegenerative disease. (2020, Nat Rev Neurol, PMID:32203399)”, “score”: 0.506, “reason”: “14 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062207-e4ce5cf0”, “quality_score”: 0.65, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-075425-2feffb0c”, “title”: “The abstract shows that acute neuroinflammation becomes persistent with a specific transcriptomic signature, but the mechanistic drivers of this transition are not explained. Understanding this switch is critical for developing interventions to prevent chronic sequelae.\n\nGap type: unexplained_observation\nSource paper: Deleterious effect of sustained neuroinflammation in pediatric traumatic brain injury. (2024, Brain, behavior, and immunity, PMID:38705494)”, “score”: 0.495, “reason”: “15 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-075425-2feffb0c”, “quality_score”: 0.83, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046_task_9aae8fc5”, “title”: “While the study establishes TDP-43 triggers mtDNA release via mPTP to activate cGAS/STING, it’s unclear why this pathway preferentially affects motor neurons in ALS when TDP-43 pathology occurs in multiple cell types. Understanding this selectivity is crucial for targeted therapeutic interventions.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. (2020, Cell, PMID:33031745)”, “score”: 0.49, “reason”: “10 token overlaps; entity overlap: pmid, sting”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046”, “quality_score”: 0.734, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}